Inovio Pharmaceuticals (AMEX:INO), developer of therapeutic and preventive vaccines against cancer and infectious diseases, said on Wednesday it plans to make presentations at scientific conferences held in the Bangkok, Italy and Singapore.
The first conference, an AIDS Vaccine conference, is slated for Sept. 12 to 15 and will take place at the Thailand Bangkok Convention Centre at CentralWorld.
Inovio’s scientific advisor, Stanley Plotkin, will present on Sept. 12 and talk about the lessons from past vaccines for an AIDS vaccine.
While Inovio collaborator Jeffrey Currier plans to discuss cell mediated immune responses after DNA delivered by either Biojector or electroporation and boosted with a heterologous insert recombinant poxvirus, on Sept. 13.
Another presenter, Jean Boyer, will speak about long-term programming of antigen-specific immunity from gene expression on Sept. 14.
Meanwhile, the second conference will take place in Italy at the Piazza del Popolo on Sept. 15 to 17. The director of product development, Amir Khan, is slated to talk about the development of DNA vaccines for cancer.
By the same token, Chief Medical Officer, Mark Bagarazzi will talk about DNA vaccines that elicit T-cell and antibody responses with the potential to treat cervical dysplasia and cancer, on Sept. 17.
The third conference, which is a vaccine forum, will be held in Singapore at the Marina Bay Sands Hotel and take place on Sept. 19 to 21.
Inovio’s Chief Executive, Joseph Kim, will partake in a panel discussion about launching higher priced products in Asia, on Sept. 20.
Kim will also make a presentation about how enhanced vaccines are developed as therapeutic vaccines for major chronic infectious diseases and cancer, on Sept. 21 at 2:15 p.m.
Blue Bell, Pennsylvania-based Inovio is developing next generation vaccines, known as DNA-based vaccines, to treat and prevent cancers and infectious diseases.
Its SynCon vaccines are designed to provide broad cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza.
Inovio’s shares were up 13 cents, or 1.98%, to trade at $0.69 Wednesday on the American Stock Exchange.
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment